Stemden

What Stemden does

Stemden Co., Ltd. is a South Korean regenerative dentistry biotech founded in 2020 as a spin-off from Pusan National University School of Dentistry's Oral Biochemistry Lab, headquartered at the Busan National University Advanced Medical Convergence Center in Yangsi. The company develops oral tissue regeneration therapeutics based on proprietary oral stem cell activation regulator technology, with a portfolio targeting regeneration of dental pulp, dentin, periodontal ligament, and alveolar bone — addressing dental caries, periodontitis, and alveolar bone loss through natural tissue regeneration rather than artificial material replacement. Its core product, Pulp Capping, is a dental pulp capping agent designed to regenerate dental pulp and dentin for cavity treatment without artificial substitution, and the pipeline extends to periodontal ligament and alveolar bone regeneration products supported by bioactive scaffold co-development with ST One.

Stemden operates a clinical-stage biopharmaceutical business model: it generates no commercial revenue today and instead monetizes through eventual product sales following clinical trial approval, with explicit plans to pursue US FDA clinical approval and global market expansion. Its R&D and clinical positioning is anchored by long-dated research collaborations with Pusan National University Dental School (technology origin) and the University of Tennessee Health Science Center (international co-development for FDA pathway), supplemented by clinical research relationships with Yangsan Pusan National University Hospital. The leadership team — CEO Jang Il-ho and Technical Director Dr. Seo Eun-jin (PhD, Oral Biochemistry) — combines commercial and deep academic expertise in dental stem cell regeneration.

The go-to-market approach is enterprise- and partnership-driven rather than direct sales: Stemden engages hospitals for clinical research collaborations, participates in startup roadshows and government-backed investment competitions (B-Startup Challenge, K-Startup, Gyeongnam Startup Korea Roadshow) for capital and visibility, and uses academic conferences (Korean Society for Stem Cell Research) for scientific validation. As of the source data, the company has raised approximately 310 million KRW (~USD 230,000) total via competition prizes and an equity-linked B-Startup Challenge award, holds domestic and international patents for non-surgical and surgical oral tissue regeneration, and has won eight regional and national innovation awards between 2021 and 2023.

Name

Stemden

Legal name

Stemden Co., Ltd.

Website

https://stemden.co.kr

Company type

Private

Founded year

2020

Operating status

Operating

Short description

Stemden is a South Korean clinical-stage regenerative dentistry biotech developing stem cell activation-based therapeutics for dental pulp, dentin, periodontal ligament, and alveolar bone regeneration, targeting dental caries and periodontitis patients with plans to enter the US market via FDA clinical approval.

Ownership category

akta.pro rank

Product category

Regenerative Dental Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI), Regenerative Endodontics (Revascularization) (HLABADAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative dentistry
• Stem cell therapy
• Dental pharmaceuticals
• Tissue regeneration
• Oral healthcare

Headquarters

HQ city

Yangsan

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Regenerative Dental Pharmaceuticals: Development and commercialization of regenerative dental pharmaceutical products including dental pulp regeneration, dentin regeneration, periodontal ligament regeneration, and alveolar bone regeneration products. Revenue will be generated through product sales upon successful clinical trials and regulatory approvals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Stemden is a regenerative dental medicine company that discovers oral stem cell activation regulators and develops them into pharmaceutical products that regenerate dental pulp, dentin, periodontal ligaments, and alveolar bone. The company focuses on cell-activation-based therapeutics delivered via human-application-compatible drug delivery systems developed with industry partners, targeting dental caries, periodontitis, and alveolar bone loss as alternatives to artificial material replacement.

Product overview

Stemden is a regenerative dental medicine company developing a portfolio of oral tissue regeneration products based on stem cell activation technology. The core product is Pulp Capping, which regenerates dental pulp and dentin to treat cavities without artificial material replacement. The company is expanding its product line to include periodontal ligament and alveolar bone regeneration products. All products utilize the company's proprietary oral stem cell activation regulator technology developed in collaboration with academic and industrial partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Pulp Capping

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered important and core.

• Yangsan Pusan National University Hospital (양산부산대병원)importantStrategic or Co-development Partner · 26 October 2022Selected as one of 5 companies for Yangsan Pusan National University Hospital's 'Buyer Core Building Project', indicating clinical research collaboration for product development.
• Pusan National University Dental School (부산대학교 치의학전문대학원)coreStrategic or Co-development Partner · 1 August 2022Multi-year collaborative research partnership for dental/oral tissue regeneration technology development. The company originated from research at Pusan National University Dental School's Oral Biochemistry Lab. Dr. Seo Eun-jin from the Oral Biochemistry Lab leads Stemden's technology development.
• University of Tennessee Health Science Center (미국 멤피스 테네시 의대)coreStrategic or Co-development Partner · 1 August 2022International collaborative research partnership for dental regeneration technology. Joint research collaboration over several years contributing to Stemden's core technology development.
• ST One (에스티원)importantTechnology or Integration · 1 August 2022Collaborative development partner specializing in bioactive-friendly scaffold production. ST One provides expertise in creating scaffolds that support tissue regeneration for dental applications.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medipost: Korean stem cell therapy company that developed Cartistem (umbilical cord blood-derived MSC product). Comparable to Stemden as a Korea-based, clinical-stage stem cell therapeutic developer with regulatory experience in biologics.
• Regedent AG: Swiss dental biotechnology company developing biologic and regenerative products for periodontal and peri-implant therapy. Highly comparable to Stemden as a specialized regenerative dentistry player with similar clinical focus.
• Pharmicell: Korean biotech focused on stem cell therapeutics including Hearticellgram-AMI. Comparable to Stemden as a Korean stem cell drug developer pursuing regulatory approval for cell-based therapies.
• botiss biomaterials: European dental regeneration company producing bone substitutes, membranes, and soft-tissue grafts for periodontal and implant dentistry. Comparable to Stemden in targeting regenerative dentistry with a portfolio of clinical products.
• Geistlich Pharma: Swiss-based global leader in dental bone and tissue regeneration (Bio-Oss, Bio-Gide). Directly comparable to Stemden as a developer and commercializer of regenerative dental products used in periodontal and bone regeneration procedures.
• NovaBone Products: US-based developer of bioactive glass-based bone regeneration products for dental and orthopedic applications. Comparable to Stemden as a specialty regenerative product company targeting dental/oral bone indications.

Emerging players

• Mesoblast: Clinical-stage cellular medicine company developing mesenchymal lineage cell therapies for inflammatory and degenerative diseases. Comparable to Stemden as a stem-cell-based therapeutic developer, though Mesoblast operates at a later clinical stage and in non-dental indications.

Broad incumbents

• Dentsply Sirona: Global dental equipment and materials incumbent with a broad regenerative and implant portfolio. Comparable to Stemden as a player in the same end market (dental tissue regeneration/restoration) but operating at vastly larger scale across many categories.
• Straumann Group: Global dental implant and regenerative leader (Straumann, Neodent, Medentika). Comparable to Stemden as a major player in dental tissue regeneration and replacement, though its portfolio spans implants, prosthetics, and digital dentistry rather than purely biologics.
• Colgate-Palmolive: Global oral care leader with regenerative and bioactive dental research programs through its research arm. Comparable to Stemden as a participant in next-generation oral tissue regeneration science, but at dramatically larger scale and broader scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stemden